The Blue Box Biomedical Solutions Analysis

Detect breast cancer early using urine samples; Provide accessible screening for women with dense breast tissue; Reduce reliance on traditional mammography; Offer a pain-free alternative for breast cancer testing; Enable gynecology clinics to adopt innovative diagnostic solutions.

Conducting clinical trials in 2025; Featured in major publications like BBC News and Vogue; Funded by the European Union's Digital Kit program.

Main Information

• Information: Breast cancer is the most treatable cancer, yet it remains the #1 cancer killer for women, as 50% are detected too late. At The Blue Box, we've built a urine-based breast cancer test with a sensitivity of 88.42%, outperforming mammography by 15%-30%. We’ll run clinical trials in 2025 and launch in gynecology clinics by 2026.
• Interests: ARTIFICIAL INTELLIGENCE, HEALTH/FITNESS/WELLBEING, IMPACT/SOCIAL INNOVATION
• Location: Hall 8.0 – 4YFN & Partner Theatres Stand 8.0D32.4
• Tagged as startup: Yes

Contact & Links

• LinkedIn: Connect on LinkedIn
• Twitter: Follow on X (formerly Twitter)
• Phone Number: +34 632920151
• Email: Email

Key Information

• Growth Stage: Seed
• Country: Spain
• Founding Year: 2021

Company Context

Company Name: The Blue Box Biomedical Solutions; Company Website: https://thebluebox.ai/